Viatris Inc.

NASDAQ:VTRS

Drug Manufacturers - Specialty & Generic

Healthcare
$20.28 -2.29%

-$0.36 today

Market cap
$23.25B
Beta
0.90
P/E (TTM)
-59.9
EPS (TTM)
-$0.26
Dividend yield
3.12%
52W Low $8.63High $17.53

Volume 13.21M

Average 10.58M

VTRS Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Viatris Inc.NASDAQ: VTRS

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income growth accelerates

Q2 FY2026 net income of $118.8M (cash outflow) rose 2482.6% year over year, ahead of the -88.2% change in trailing-twelve-month net income.

Context

  • Net income amounted to 24.6% of revenue in FY2025, up 20.3 pp from a year earlier.
  • Net income increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 7 analysts of $3.03B (+186.1%) for the fiscal year ending Dec 2026, a slowdown from the +454.2% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$118.8M-167.3% QoQ
Last fiscal yearDec 2025
-$3.51B+454.2% YoY
LTMJun 2026
-$410.7M-88.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2482.6%+670.4%-1812.2 pp
1 year+454.2%+186.1%-268.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(3.51B) USD
Year-over-year change
-454.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How VTRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -88.2% is the 7th highest of 10, against a peer median of -44.1%.
  • Net income amounts to 2.8% of revenue for VTRS, versus a peer median of 8.4%.
VTRS Competitors
Net Income for VTRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹27.72B INR-52.4%+0.0%8.4%
HLNHaleon plcFY2025£1.63B GBP+13.1%+13.4%14.8%
BHCBausch Health Companies Inc.LTM Jun 2026$1.1B USD-2132.0%—10.2%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$709M USD+537.7%—4.1%
VTRSViatris Inc.LTM Jun 2026$410.7M USD-88.2%—2.8%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$215.32M USD+320.2%—6.9%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$90.09M USD+528.0%—9.8%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$79.23M USD-44.1%+2.4%11.0%
OGNOrganon & Co.LTM Sep 2026$40.75M USD-108.1%-41.1%0.7%
ALKSAlkermes plcLTM Sep 2026$351K USD-100.1%—0.0%
Peer median (excluding VTRS) —-44.1%+1.2%8.4%

Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.27B)2.08B54.7M(634.2M)(3.51B)
Depreciation & Amortization4.51B3.03B2.74B2.71B2.8B
Deferred Income Tax675.7M(25.9M)(387.1M)(767.6M)(476.5M)
Stock-Based Compensation111.2M116.4M180.7M146.1M177.7M
Change in Working Capital(1.8B)(922.6M)(711.3M)(318.6M)(2.5B)
Accounts Receivables59.3M(240.3M)78.6M300.1M334.6M
Inventory(427.6M)(259.5M)(613.3M)(723.4M)(106.4M)
Accounts Payables(70.4M)170.2M314.7M36M(168M)
Other Working Capital(1.37B)(593M)(491.3M)68.7M(2.56B)
Other Non-Cash Items797.4M(1.28B)922.1M1.17B5.84B
Operating Cash Flow3.02B3B2.8B2.3B2.32B
Capital Expenditures(509.4M)(489.4M)(474.5M)(326M)(378.8M)
Acquisitions (Net)277M0(667.7M)(350M)0
Purchases of Investments(30.2M)(30.2M)(26.3M)(26M)(23.9M)
Sales of Investments29.8M29.9M26.3M26M23.9M
Other Investing Activities115M1.96B280.6M2.48B(48.9M)
Investing Cash Flow(117.8M)1.47B(764.1M)1.8B(427.7M)
Debt Repayment(2.1B)(3.28B)(1.25B)(3.71B)100K
Common Stock Issued03.3M3.1M2.5M2.6M
Common Stock Repurchased(17.4M)0(250M)(250M)(500.5M)
Dividends Paid(399M)(581.6M)(575.6M)(574.8M)(561.2M)
Other Financing Activities(496.5M)(19.5M)(229.8M)205.6M(234.9M)
Financing Cash Flow(3.01B)(3.88B)(2.3B)(4.33B)(1.29B)
Effect of Forex Changes(30.9M)(38.9M)(2.5M)(30.7M)17.6M
Net Change in Cash(143.8M)556.3M(268.9M)(257.5M)611.9M
Free Cash Flow2.51B2.51B2.33B1.98B1.94B

Viatris Inc.

NASDAQ:VTRS

Intrinsic Alpha fair value

Locked

Current Price

$20.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.